Biomedical subjects
Bernard Goldman
Publications and source records attributed to Bernard Goldman.
The recall genie: time to go back in the bottle.
Explore the source record for details and available documents.
Durability and prevalence of aortic regurgitation nine years after aortic valve replacement with the Toronto SPV stentless bioprosthesis.
BACKGROUND AND AIM OF THE STUDY: Stentless aortic bioprostheses have excellent hemodynamics. Previous investigations of the Toronto SPV valve described a correlation between the occurrence of significant aortic regurgitation (AR) and dilation of the sinotubular junction. The study aim was to determine the long-term durability and determinants of AR at nine years in a large, multicenter study of the Toronto SPV valve. METHODS: The study included 447 patients from six centers. Clinical outcomes and echocardiographic data (gradients, effective orifice area index (EOA-I), left ventricular mass, aortic root dimensions, and presence and severity of AR) were collected prospectively. A multivariable logistic regression model was used to evaluate clinical and echocardiographic variables for impact on the occurrence of AR. RESULTS: Total follow up was 2,660 patient-years (mean 6.0 +/- 2.5 years; range: 0 to 11.1 years). Mean gradient and EOA-I remained unchanged through nine years. There were 17 cases of structural deterioration, of which 15 underwent explantation. The mechanism of failure was predominantly leaflet tear in the setting of sinotubular dilation. Freedom from explant for structural failure was 90.1% at nine years (100% for patients aged > or = 65 years). Freedom from hemodynamically significant AR was 96.9% at five years and 82.5% at nine years. Determinants of AR were longer duration of follow up, larger valve size, and increase in the ratio of sinotubular junction to the size of valve implanted. CONCLUSION: At nine years after implantation of the Toronto SPV valve, hemodynamics remained excellent. There was good freedom from structural deterioration through nine years, and structural failure occurred due to aortic root dilation and leaflet tear, without significant valve calcification. AR tends to occur with longer follow up, larger valve sizes, and dilation of the sinotubular junction.
Impact of preoperative renal dysfunction on cardiac surgery results.
Results of cardiac surgery were analyzed using a database that included plasma creatinine levels in 2,214 patients, of whom 507 had preoperative renal dysfunction (creatinine clearance < 0.9 mL x s(-1) x m(-2)). Logistic regression and propensity score analyses found preoperative renal dysfunction to be an independent predictor of morbidity and mortality. Plotting preoperative creatinine clearance against morbidity and mortality revealed an exponential increase in morbidity and mortality when preoperative creatinine clearance was < 0.84 mL x s(-1) x m(-2). Patients were stratified for age, operative procedure, and comorbidity. In all stratified groups, preoperative creatinine clearance < 0.84 mL x s(-1) x m(-2) was associated with similar exponential increases in morbidity and mortality. In patients with preoperative renal dysfunction, elevated plasma creatinine levels persevered for 6 months postoperatively. Dialysis beyond postoperative day 10 was required in < 2% of patients with preoperative plasma creatinine of 160-200 micro mol x L(-1) and in 5% in those with creatinine > 200 micro mol x L(-1) (p < 0.05). Actuarial survival was significantly reduced (< 90% at 18 months postoperatively) in patients with preoperative renal dysfunction.
Impact of small valve size on hemodynamics and left ventricular mass regression with the Toronto SPV stentless aortic bioprosthesis.
BACKGROUND AND AIM OF THE STUDY: The hemodynamic performance of stentless aortic bioprostheses has been previously well described. Because the potential for prosthesis-patient mismatch is greatest for small valves in the aortic position, the present study sought to compare the hemodynamic performance and degree of left ventricular (LV) mass regression between valve sizes for the Toronto SPV valve, with special interest in measures of relief of LV outflow obstruction afforded by the smallest valves. METHODS: This study included 257 patients (178 men, 79 women; mean age 63.5+/-11.4 years; range: 34-93 years) from six investigative centers with complete echocardiography/Doppler data obtained through three years. Valve sizes implanted were 21 mm (n = 11), 23 mm (n = 23), 25 mm (n = 58), 27 mm (n = 83), and 29 mm (n = 82). Echocardiography was performed at discharge, six months, one year, and yearly thereafter, and interpreted in a centralized core laboratory. Mean gradient, effective orifice area (EOA), indexed EOA, and absolute and percent change in LV mass index were used as markers of hemodynamic performance. RESULTS: For all valve sizes, mean and peak gradients fell and EOA increased early after surgery. There were no differences between groups in the degree to which gradients fell, and EOA increased from discharge to one year follow up. At one year, indexed EOA was 0.9 cm2/m2 for valve sizes 21 and 23 mm, and 1.0-1.2 cm2/m2 for sizes 25, 27 and 29 mm. There was statistically significant LV mass regression for all valve sizes (p <0.05), and no differences between valve sizes in the magnitude of absolute or percent change in LV mass index between baseline and three years. CONCLUSION: The Toronto SPV valve demonstrates excellent parameters of hemodynamic performance for all valve sizes, including the smallest valves used in only a minority of patients. Findings of indexed EOA > or = 0.9 cm2/m2, and equivalent degrees of LV mass regression for all valve sizes, reinforces the excellent hemodynamic performance of stentless aortic bioprostheses, and suggests that prosthesis-patient mismatch should be minimized with these valves.